CompletedNCT00391261
Metformin for weight gain from antipsychotic medicines in children and adolescents
About this title
Read the official source — NCT00391261Medication studyAges 10–18United StatesSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 10 years to 18 years.
- Listed locations
- MedfordSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateJuly 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 11
- Sponsor
- Cambridge Health Alliance
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 10 Years to 18 Years
- Official registry ID
- NCT00391261
- Official title
Show the full official title
A Prospective Open-label Trial of Metformin for Weight Control of Pediatric Patients on Atypical Antipsychotic Medications.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Medford
Questions about this study
Who is behind this study?
The study sponsor is Cambridge Health Alliance.
Did this study involve medication?
Yes. The study involved medication, including Metformin.
Who was this study for?
Listed age limits: 10 years to 18 years.
